# **BIOLIDICS LIMITED**

(Company Registration Number: 200913076M)

## ANNOUNCEMENT PURSUANT TO RULE 706A OF THE LISTING MANUAL

Pursuant to Rule 706A of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"), the board of directors (the "**Board**") of Biolidics Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to announce the following acquisition of shares that occurred during the half year ended 30 June 2020.

## ACQUISITION OF A SUBSIDIARY COMPANY

On 27 March 2020, the Company announced that it had entered into a sale and purchase agreement with SAM Laboratory Pte. Ltd. (the "**Vendor**", and together with its holding company and subsidiaries, the "**Vendor Group**") for the proposed acquisition (the "**Acquisition**") of the entire issued and paid-up ordinary shares ("**Sale Shares**") in the capital of Biomedics Laboratory Pte. Ltd. ("**Biomedics**"). The Acquisition was completed on 26 May 2020. The details of the Acquisition are set out below.

Consideration	<ul> <li>The aggregate consideration for the Sales Shares was \$\$3,500,000 (the "Consideration"). Where the Deferred Consideration (as defined below) is paid after 12 months (but not later than 24 months) from the Completion Date (as defined below), the Consideration shall be \$\$3,700,000.</li> <li>The Consideration shall be satisfied in full by way of bank transfer of immediately available funds as follows:</li> <li>(a) \$\$100,000 was payable upon completion of the Acquisition (the "Completion") (the "Initial Payment"); and</li> <li>(b) the remaining amounts being the Consideration less the Initial Payment (the "Deferred Consideration") shall be payable no later than 24 months from the date of Completion (the "Completion by providing not less than 10 days of written notice to the Vendor of such payment.</li> <li>The Consideration was determined based on arm's length negotiations and arrived at on a willing seller willing buyer basis, after taking into consideration, amongst others, the time and financial resources required ("CAP-accredited") clinical laboratory, the purchase consideration for the Group to set up a College of American Pathologists accredited ("CAP-accredited") clinical laboratory, the purchase consideration for the purchase of entire issued and paid-up share capital of the Vendor by the Vendor Group from Singapore Institute of</li> </ul>
	Advanced Medicine Holdings Pte. Ltd. in 2017 (the "2017 Transaction"), the expanded range of services, customer base and revenue growth of the clinical laboratory business since the 2017 Transaction, the market value of the Sale Shares based on the valuation report, and the rationale for and benefits of the Acquisition, in particular, the potential growth and prospects of the Group arising from the acquisition of a CAP-accredited clinical laboratory.
Net asset value	Based on the unaudited management accounts as at 31 December 2019, the net tangible assets of Biomedics was S\$400,001.

Please refer to the Company's announcements dated 27 March 2020 and 26 May 2020 and the Circular to Shareholders dated 8 April 2020 in relation to the Acquisition for further details.

#### BY ORDER OF THE BOARD

#### Yee Pinh Jeremy Non-Executive Non-Independent Chairman 14 August 2020

This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.